The Court ruled to uphold a December 15, 2014 preliminary injunction requiring Actavis to continue distribution of Namenda 5mg and 10mg tablets. Forest Laboratories, a wholly owned subsidiary of Actavis, had previously announced plans to discontinue sales of the drug in the fall of 2014.
Namenda is an NMDA receptor antagonist approved for the treatment of moderate-to-severe dementia of the Alzheimer’s type. It is also available as Namenda oral solution and Namenda XR extended-release capsules.
For more information call (844) 873-2823 or visit Namenda.com.